Practical integration of ctDNA-defined minimal residual disease in gastrointestinal cancers: testing windows and evidence-aligned management frameworks.
Doctors now have practical guidance for using blood-based cancer DNA tests to detect early recurrence in colorectal and GI cancers.
Yao N et al. reviewed the practical integration of ctDNA-defined minimal residual disease (MRD) testing in gastrointestinal cancers, proposing evidence-aligned testing windows and clinical management frameworks. This review provides actionable guidance for clinicians seeking to implement ctDNA-based MRD monitoring in colorectal and other GI malignancies.
What the study was
- Study design
- Narrative/systematic review with clinical framework development
- Population
- Patients with gastrointestinal cancers (colorectal, gastric, others)
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Clinical & translational oncology
Why it surfaced
Directly matches watchlist topic for ctDNA/liquid biopsy early detection; provides practical clinical implementation framework for ctDNA MRD in GI cancers — translational value is high. FLAG-driven HIGH (EARLY_CANCER_DETECTION).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.